[go: up one dir, main page]

CO2017010019A2 - Bloqueador de ácido competitivo con potasio (p-cab) - Google Patents

Bloqueador de ácido competitivo con potasio (p-cab)

Info

Publication number
CO2017010019A2
CO2017010019A2 CONC2017/0010019A CO2017010019A CO2017010019A2 CO 2017010019 A2 CO2017010019 A2 CO 2017010019A2 CO 2017010019 A CO2017010019 A CO 2017010019A CO 2017010019 A2 CO2017010019 A2 CO 2017010019A2
Authority
CO
Colombia
Prior art keywords
cab
potassium
acid blocker
competitive acid
competitive
Prior art date
Application number
CONC2017/0010019A
Other languages
English (en)
Inventor
Richard Jenkins
Mark Hibberd
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55806738&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2017010019(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1505526.2A external-priority patent/GB201505526D0/en
Priority claimed from GBGB1521015.6A external-priority patent/GB201521015D0/en
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of CO2017010019A2 publication Critical patent/CO2017010019A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención proporciona un bloqueador de ácido competitivo con potasio (P-CAB) para usarse en el tratamiento, prevención y/o reducción de síntomas de la enfermedad por reflujo gastroesofágico (ERGE) en pacientes que responden de manera parcial a un inhibidor de la bomba de protones (IBP). El P-CAB puede, por ejemplo, seleccionarse de 1-[5-(2-fluorofenil)-1-(piridin-3-ilsulfonil)-1H-pirrol-3-il]-N-metilmetanamina (vonoprazan), revaprazan (YH1855), YH4808, RQ-4 y CS-526, o una sal de los mismos.
CONC2017/0010019A 2015-03-31 2017-10-03 Bloqueador de ácido competitivo con potasio (p-cab) CO2017010019A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1505526.2A GB201505526D0 (en) 2015-03-31 2015-03-31 Novel pharmaceutical uses
GBGB1521015.6A GB201521015D0 (en) 2015-11-27 2015-11-27 Novel pharmaceutical uses
PCT/JP2016/061185 WO2016159386A1 (en) 2015-03-31 2016-03-30 Novel pharmaceutical uses

Publications (1)

Publication Number Publication Date
CO2017010019A2 true CO2017010019A2 (es) 2018-02-20

Family

ID=55806738

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2017/0010019A CO2017010019A2 (es) 2015-03-31 2017-10-03 Bloqueador de ácido competitivo con potasio (p-cab)

Country Status (22)

Country Link
US (2) US20180085361A1 (es)
EP (1) EP3277279A1 (es)
JP (1) JP2018513140A (es)
KR (1) KR20170132260A (es)
CN (1) CN107530335A (es)
AU (1) AU2016241069A1 (es)
BR (1) BR112017021024A2 (es)
CA (1) CA2981244A1 (es)
CL (1) CL2017002325A1 (es)
CO (1) CO2017010019A2 (es)
CR (1) CR20170404A (es)
DO (1) DOP2017000218A (es)
EA (1) EA201792148A1 (es)
EC (1) ECSP17072984A (es)
IL (1) IL254419A0 (es)
MA (1) MA41850A (es)
MX (1) MX2017012414A (es)
PE (1) PE20180195A1 (es)
PH (1) PH12017501751A1 (es)
SG (1) SG11201706739WA (es)
TN (1) TN2017000416A1 (es)
WO (1) WO2016159386A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018510190A (ja) 2015-03-31 2018-04-12 ミュタビリスＭｕｔａｂｉｌｉｓ 複素環式化合物及びそれらの細菌感染症の予防または治療のための使用
BR112020000318A2 (pt) 2017-07-10 2020-07-14 Takeda Pharmaceutical Company Limited preparação
CN114642642A (zh) * 2020-12-18 2022-06-21 上海天慈生物谷生物工程有限公司 5-(2-氟苯基)-n-甲基-1-(3-吡啶基磺酰基)-1h-吡咯-3-甲胺制剂
KR102851644B1 (ko) * 2021-07-28 2025-08-28 대봉엘에스 주식회사 보노프라잔 공형성화물, 및 이의 제조방법
KR20250036905A (ko) * 2022-08-04 2025-03-14 쟝쑤 케어파르 파마슈티컬 컴퍼니 리미티드 피롤류 위산분비 억제제를 함유하는 약물 조성물 및 그 제조 방법
CN116270443A (zh) * 2022-10-27 2023-06-23 广州白云山天心制药股份有限公司 富马酸伏诺拉生注射液及其制备方法
CN115944743B (zh) * 2023-01-18 2025-08-08 山东诚成医药科技有限公司 一种富马酸伏诺拉生组合物及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100958829B1 (ko) 2004-09-03 2010-05-25 주식회사유한양행 피롤로[2,3-ｃ]피리딘 유도체 및 그의 제조방법
WO2008130863A2 (en) * 2007-04-11 2008-10-30 Auspex Pharmaceuticals, Inc. Substituted benzimidazoles
NZ602592A (en) 2008-07-28 2014-01-31 Takeda Pharmaceutical Light irradiation resistant pharmaceutical composition
MX2012000275A (es) * 2009-07-09 2012-02-08 Raqualia Pharma Inc Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.
US20120070468A1 (en) * 2010-09-16 2012-03-22 Uop Llc Removal of toxins from gastrointestinal fluids
US9487485B2 (en) 2013-02-28 2016-11-08 Takeda Pharmaceutical Company Limited Method for producing sulfonyl chloride compound
CN103951652B (zh) * 2014-04-18 2015-09-23 潍坊博创国际生物医药研究院 5-(2-氟苯基)-n-甲基-1-(3-吡啶基磺酰基)-1h-吡咯-3-甲胺水溶性有机酸盐和注射剂及它们的制备方法

Also Published As

Publication number Publication date
JP2018513140A (ja) 2018-05-24
TN2017000416A1 (en) 2019-01-16
BR112017021024A2 (pt) 2018-07-03
US20190070159A1 (en) 2019-03-07
CR20170404A (es) 2018-01-10
CL2017002325A1 (es) 2017-12-29
IL254419A0 (en) 2017-11-30
EA201792148A1 (ru) 2018-02-28
DOP2017000218A (es) 2018-01-31
PH12017501751A1 (en) 2018-04-11
CA2981244A1 (en) 2016-10-06
US20180085361A1 (en) 2018-03-29
ECSP17072984A (es) 2018-02-28
EP3277279A1 (en) 2018-02-07
KR20170132260A (ko) 2017-12-01
AU2016241069A1 (en) 2017-09-21
MX2017012414A (es) 2018-01-26
PE20180195A1 (es) 2018-01-26
MA41850A (fr) 2018-02-06
WO2016159386A1 (en) 2016-10-06
CN107530335A (zh) 2018-01-02
SG11201706739WA (en) 2017-09-28

Similar Documents

Publication Publication Date Title
CO2017010019A2 (es) Bloqueador de ácido competitivo con potasio (p-cab)
CY1123833T1 (el) Μεθοδοι προληψης καρδιαγγειακων συμβαντων σε δυσλιπιδαιμικους πληθυσμους υπολειπομενου κινδυνου
AR090269A1 (es) Composicion farmaceutica y sus usos
CO2017004715A2 (es) Métodos y formulaciones para tratar enfermedades vasculares de los ojos
JO3653B1 (ar) ترايازول عوامل مساعدة لمستقبل apj
MX2021014242A (es) Uso de linagliptina en terapia antidiabetica cardio- y renoprotectora.
MX381599B (es) Empagliflozina para usarse en el tratamiento de micro y macroalbuminuria
BR112015009948A2 (pt) antagonistas de ativina-actriia e usos para tratamento ósseos e outros disturbios
DK2719708T3 (da) Materiale og fremgangsmåder til behandling eller forebyggelse af her-3-relaterede sygdomme
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
MX2017006275A (es) Inhibidor de cinasa aurora a.
MX2019010707A (es) Metodos para tratar y/o prevenir queratosis actinica.
EA201692470A1 (ru) Фармацевтические комбинации
DK3687567T3 (da) Anti-adrenomedullin (adm) bindemiddel til brug i behandling eller forebyggelse af sygdomssymptomer
AR094707A1 (es) Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2
MX392182B (es) Combinaciones de dosis fija y formulaciones que comprenden ácido 8-hidroxi-2,2,14,14 tetrametilpentadecanodioico (etc1002) y ezetimiba y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
WO2017208174A3 (en) Methods of treating disease with pfkfb3 inhibitors
MX388815B (es) Inhibidores de il-8 para usarse en el tratamiento de neuropatia periferica inducida por quimioterapia.
CL2015001564A1 (es) Composición que comprende una triazina y su uso en el tratamiento intramuscular de coccidiosis o enfermedad protozoaria relacionada, en un mamífero no humano.
CO2017008115A2 (es) Ácido (2s,4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-4-(etoxioxalilamino)-2-hidroximetil-2-metilpentanoico
PE20170469A1 (es) Metodos para mejorar el rendimiento miocardico en pacientes con cirugia de fontano que utilizan composiciones de udenafilo
EA201691498A1 (ru) Новая мишень для лечения и профилактики диабета
MX391376B (es) Composiciones de la membrana de la cáscara del huevo para usarse en el tratamiento de la cadena ligera kappa del factor nuclear de las células b activadas (nf-kb) en un organismo hospedero.
ECSP089024A (es) Camsilato de (s)-(-)-amlodipino o hidrato del mismo y composición farmacéutica que comprende el mismo
AR103219A1 (es) Compuesto de (1h-indol-3-il)propan-1-ona, composición farmacéutica, combinación y mezcla que lo comprenden y su uso para la fabricación de un medicamento